D. Western Therapeutics Institute, Inc.

Equities

4576

JP3548740004

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 am EDT			5-day change	1st Jan Change
110 ^JPY	+4.76%		+1.85%	-21.99%

Feb. 14	D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024	CI
2023	D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2023	CI

D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

May 13, 2022 at 03:00 am EDT

D. Western Therapeutics Institute, Inc. provided earnings guidance for the fiscal year ending December 31, 2022. The company expects net sales to be JPY 370 million, Operating loss to be JPY 690 million, loss attributable to owners of parent to be JPY 670 million or JPY 22.82 per basic share.

Latest news about D. Western Therapeutics Institute, Inc.

D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024	Feb. 13	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2023	23-08-09	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024	23-05-15	CI
D. Western Therapeutics Institute, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023	23-02-14	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022	22-11-11	CI
D. Western Therapeutics Institute, Inc. announced that it has received ¥901.216203 million in funding from Whiz Partners Inc.	22-07-18	CI
D. Western Therapeutics Institute, Inc. announced that it expects to receive ¥901.216203 million in funding from Whiz Partners Inc.	22-06-19	CI
D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022	22-05-13	CI
D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022	22-02-14	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021	21-11-12	CI
D. Western Therapeutics Institute, Inc. Announces Consolidated Earnings Results for the Six Months Ended June 30, 2021	21-08-11	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021	21-08-11	CI
UBiENCE Inc. announced that it expects to receive ¥100 million in funding from D. Western Therapeutics Institute, Inc.	21-06-16	CI
D. Western Therapeutics Institute, Inc. Reports Consolidated Financial Results for the First Quarter Ended March 31, 2021	21-05-12	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021	21-05-12	CI
D. Western Therapeutics Institute, Inc. Reports Consolidated Financial Results for the Year Ended December 31, 2020	21-02-11	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021	21-02-11	CI
D. Western Therapeutics Institute, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2020	20-11-13	CI
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2020	20-11-13	CI
D. Western Therapeutics Institute, Inc. Announces Consolidated Earnings Results for the Sis Months Ended June 30, 2020	20-08-14	CI
D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2020	20-08-14	CI
D. Western Therapeutics Institute, Inc. announced that it has received ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm	20-08-06	CI
D. Western Therapeutics Institute, Inc. announced that it expects to receive ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm	20-07-21	CI
D. Western Therapeutics Institute, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2020; Provides Earnings Guidance for the Full Year Ending December 31, 2020	20-05-15	CI

Chart D. Western Therapeutics Institute, Inc.

Duration

Period

Chart D. Western Therapeutics Institute, Inc.

More charts

Company Profile

D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Companyâs drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
D. WESTERN THERAPEUTICS INSTITUTE, INC.	-21.99%	22.98M
VERTEX PHARMACEUTICALS INCORPORATED	-1.14%	103B
REGENERON PHARMACEUTICALS, INC.	+7.54%	101B
ARGENX SE	+4.72%	23.07B
BIONTECH SE	-12.66%	22.23B
GENMAB A/S	-4.59%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.29%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+7.14%	14.07B
SAREPTA THERAPEUTICS, INC.	+37.88%	12.35B

Bio Therapeutic Drugs